Expertise in
1
conditions

Dr. Shaachi Gupta

Hematology | Oncology
Florida Cancer Specialist And Research Institute, LLC
1309 N Flagler Dr, 
West Palm Beach, FL 
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
Florida Cancer Specialist And Research Institute, LLC
1309 N Flagler Dr, 
West Palm Beach, FL 

Overview

Shaachi Gupta is a Hematologist and an Oncologist practicing medicine in West Palm Beach, Florida.

Dr. Gupta is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Thymic Epithelial Tumor, and Malignant Mixed Mullerian Tumor.

Dr. Gupta is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, participating in 5 clinical trials. Dr. Gupta is currently accepting new patients.

Graduate Institution

S.N. Medical College-Agra University

Residency

Maimonides Medical Center , Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Fellowships

Harvard Medical School , Internal Medicine

Hospital Affiliations

Wellington Regional Medical Center
Bethesda Hospital East
Jupiter Medical Center
Good Samaritan Medical Center
Hca Florida Jfk Hospital
Jupiter Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Florida Cancer Specialist And Research Institute, Llc
1309 N Flagler Dr, West Palm Beach, FL 33401
Other Locations
Florida Cancer Specialists Pl
1309 N Flagler Dr, West Palm Beach, FL 33401
Florida Cancer Specialists Pl
5507 S Congress Ave Ste 130, Atlantis, FL 33462

Additional Areas of Focus

Dr. Gupta has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials
Similar Doctors
Expertise in
74
conditions
Dr. Warren S. Brenner
Hematology | Oncology
Expertise in
74
conditions
Dr. Warren S. Brenner
Hematology | Oncology
Referral may be required

Baptist Health Lynn Cancer Institute | Boca Raton

701 NW 13th St, 
Boca Raton, FL 
 (25.3 miles away)
561-639-8831
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Warren Brenner is a Hematologist and an Oncologist practicing medicine in Boca Raton, Florida. Dr. Brenner is highly rated in 74 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Squamous Cell Carcinoma of the Anal Canal (SCAC), and Familial Colorectal Cancer. Dr. Brenner is currently accepting new patients.

Expertise in
11
conditions
Dr. Jose Lutzky
Hematology | Oncology
Expertise in
11
conditions
Dr. Jose Lutzky
Hematology | Oncology
Referral may be required
2111 Sole Mia Way 5th, 
Miami, FL 
 (57.5 miles away)
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jose Lutzky, M.D., is a triple board-certified hematologist and oncologist at Sylvester Comprehensive Cancer Center. At Sylvester, Dr. Lutzky works as part of a multidisciplinary team of cancer experts and researchers. He earned his medical degree from Universidade Federal do Rio Grande do Sul. Dr. Lutzky is fluent in Spanish and Portuguese and his career highlights include: Recognized for his expertise in melanoma, basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma. Triple board certified in hematology, oncology and internal medicine Completed his residency in internal medicine at Mount Sinai Medical Center in Miami Beach, Florida Fellowship in hematology/oncology at Columbia Universitys New York-Presbyterian Hospital Extensive clinical research experience and interests Authored numerous articles and abstracts Fellow of the American College of Physicians. Dr. Lutzky is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Uveal Melanoma. Dr. Lutzky is currently accepting new patients.

Expertise in
10
conditions
Dr. Michel Vulfovich
Hematology | Oncology
Expertise in
10
conditions
Dr. Michel Vulfovich
Hematology | Oncology
Referral may be required

Memorial Cancer Institute

1150 N 35th Ave Ste 330, 
Hollywood, FL 
 (49.2 miles away)
954-932-2194
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michel Vulfovich is a Hematologist and an Oncologist practicing medicine in Hollywood, Florida. Dr. Vulfovich is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobin SC Disease, Familial Colorectal Cancer, and Cervical Cancer. Dr. Vulfovich is currently accepting new patients.

Frequently Asked Questions about Dr. Shaachi Gupta

How do I make an appointment with Dr. Shaachi Gupta?

You can book an appointment with Dr. Shaachi Gupta by calling their office at 561-366-4100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shaachi Gupta a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shaachi Gupta is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shaachi Gupta specialize in?

While Dr. Shaachi Gupta is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Thymic Epithelial Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Shaachi Gupta accept my insurance?

Dr. Shaachi Gupta accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-366-4100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gupta's expertise for a condition
ConditionClose
      View All 73 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile